<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>15</volume><submitter>Kong Y</submitter><pubmed_abstract>&lt;h4>Background&lt;/h4>Colorectal cancer (CRC) is one of the most common cancers worldwide. Colonoscopy is the gold standard for CRC screening, but its effectiveness in population-based programs requires further evaluation.&lt;h4>Methods&lt;/h4>We conducted a follow-up study in Xuzhou, China. Participants were recruited from 2014 to 2021, with follow-up continuing until December 2023. The study comprised two components: 1) an active follow-up to assess treatment outcomes for patients with colorectal advanced neoplasia (CAN) detected during screening; 2) a passive follow-up to compare CRC incidence and mortality between participants who underwent colonoscopy and those who refused it.&lt;h4>Results&lt;/h4>The active follow-up included 196 participants, while 15,440 were included the passive follow-up (4,029</pubmed_abstract><journal>Frontiers in oncology</journal><pagination>1689066</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC12646884</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Effect of colonoscopy screening on the risk of colorectal cancer in China: a follow-up study.</pubmed_title><pmcid>PMC12646884</pmcid><pubmed_authors>Zhang G</pubmed_authors><pubmed_authors>Jin R</pubmed_authors><pubmed_authors>Dong Z</pubmed_authors><pubmed_authors>Ma Y</pubmed_authors><pubmed_authors>Zhang P</pubmed_authors><pubmed_authors>Zhuo L</pubmed_authors><pubmed_authors>Dong D</pubmed_authors><pubmed_authors>Liu</pubmed_authors><pubmed_authors>Luo X</pubmed_authors><pubmed_authors>Wang Y</pubmed_authors><pubmed_authors>Kong Y</pubmed_authors><pubmed_authors>Gao S</pubmed_authors><pubmed_authors>Zhao H</pubmed_authors></additional><is_claimable>false</is_claimable><name>Effect of colonoscopy screening on the risk of colorectal cancer in China: a follow-up study.</name><description>&lt;h4>Background&lt;/h4>Colorectal cancer (CRC) is one of the most common cancers worldwide. Colonoscopy is the gold standard for CRC screening, but its effectiveness in population-based programs requires further evaluation.&lt;h4>Methods&lt;/h4>We conducted a follow-up study in Xuzhou, China. Participants were recruited from 2014 to 2021, with follow-up continuing until December 2023. The study comprised two components: 1) an active follow-up to assess treatment outcomes for patients with colorectal advanced neoplasia (CAN) detected during screening; 2) a passive follow-up to compare CRC incidence and mortality between participants who underwent colonoscopy and those who refused it.&lt;h4>Results&lt;/h4>The active follow-up included 196 participants, while 15,440 were included the passive follow-up (4,029</description><dates><release>2025-01-01T00:00:00Z</release><publication>2025</publication><modification>2026-06-05T16:49:10.923Z</modification><creation>2026-05-19T03:11:41.274Z</creation></dates><accession>S-EPMC12646884</accession><cross_references><pubmed>41312170</pubmed><doi>10.3389/fonc.2025.1689066</doi></cross_references></HashMap>